Abstract
Mantle Cell Lymphoma (MCL) is an uncommon but aggressive form of non-Hodgkin’s lymphoma. The extranodal involvement is not unusual especially in bone marrow, spleen, gastrointestinal tract and Waldeyer’s ring. Ocular involvement is very exceptional and the most commonly affected site is the orbit (90%), followed by the lacrimal gland (50%) and the eyelids (50%). Today, PET/CT is widely used in non-Hodgkin’s lenfoma especially in staging and evaluation of treatment response. Authors report MCL with ocular involvement that was detected on PET/CT scan.
Conflict of interest:None declared.
Keywords: Lymphoma, non-Hodgkin; positron-emission tomography; eyelid disease
CASE REPORTS
Mantle Cell Lymphoma (MCL) has been diagnosed with scalene lymph node biopsy in a 63-year-old woman. At the time of diagnosis, the disease was at stage 4B with mediastinal, cervical, hilar, abdominal lymph nodes which were detected by CT (computerized tomography). There was also bone marrow involvement. She received chemotherapy and complete response was confirmed with control CT scans. The first PET/CT scan performed at this period was normal. She has been followed up disease free for about six months. Then she complained about cervical mass and bilateral eyelid swelling. Regarding to second PET/CT findings which was performed for restaging, she received chemotherapy again for the relapse in the cervical, mediastinal, hilar, abdominopelvic and inguinal lymph nodes. A slight FDG uptake was also seen at both eyelids on this second PET/CT. She was followed for a period of time without any medical treatment in accordance with the patient's request. Eight months later an inguinal lymph node was recognized and excisional biopsy revealed recurrence. She received of chemotherapy again and then third PET/CT was performed for restaging of the disease. In the maximum intensity projection (MIP) image of whole body, in the third PET/CT scan (Figure 1) showed pathological FDG uptake at multiple lymph nodes in the head and neck, chest, abdomen and inguinal regions, and diffusely in the stomach. Axial image of the orbita in the first PET/CT image showed no pathological ocular FDG uptake (Figure 2). After about 2 years, however, axial image of orbita in third PET/CT represented diffuse FDG uptake at both eyelids (Figure 3), significantly different from the first scan. There may be a physiological uptake at the extraocular muscles, but in this case, comparison of first and third PET/CT scan showed that the FDG uptake in the muscles can be easily recognized as pathological with increase in thickness of the muscles in CT (1).
Figure 1. Maximum intensity projection (MIP) image of whole body in the third PET/CT scan. Pathological FDG uptake was seen at multiple lymph nodes in the head and neck, chest, abdomen and inguinal regions, and in the stomach.

Figure 2. Axial CT and PET images of the orbita in the first PET/CT scan.

Figure 3. Axial CT and PET images of the orbita in the third PET/CT scan.

MCL is an uncommon but aggressive form of non-Hodgkin’s lymphoma. The extranodal involvement is not unusual, especially in bone marrow, spleen, gastrointestinal tract and Waldeyer’s ring (2,3). Such localizations (breast, ocular adnexal region, skin etc.) are exceptional in MCL (4). The most commonly affected site of ocular involvement is the orbit (90%), followed by the lacrimal gland (50%) and the eyelids (50%) (5,6). MCL presenting in the ocular adnexal region has a male predominance and is associated with stage III/IV disease. Our stage IV patient did not have any ocular symptoms at diagnosis, however as the disease proceeded, severe eyelid edema occurred showing diffuse spread of the disease supported by PET/CT findings. We report an uncommon case with MCL; ocular involvement that was detected on PET/CT scan. This case reveals the need of total body PET/CT imaging in patients with aggressive non-Hodgkin’s lymphoma in order not to miss an exceptional involvement.
References
- 1.Valenzuela AA, Allen C, Grimes D, Wong D, Sullivan TJ. Positron Emission Tomography in the Detection and Staging of Ocular Adnexal Lymphoproliferative Disease. Ophthalmology. 2006;113:2331–2337. doi: 10.1016/j.ophtha.2006.05.059. [DOI] [PubMed] [Google Scholar]
- 2.Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood. 1997;15:2067–2078. [PubMed] [Google Scholar]
- 3.Bosch F, Lopez-Guillermo A, Campo E, Ribera JM, Conde E, Piris MA, Vallespi T, Woessner S, Montserrat E. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer. 1998;1:567–575. doi: 10.1002/(sici)1097-0142(19980201)82:3<567::aid-cncr20>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
- 4.Boullanger N, Renou P, Dugay J, Boyer J, Yberlucea LR, de, Combe M, Coulon MA. Palpable mantle cell lymphoma in the breas. Presse Med. 2001;30:163–165. [PubMed] [Google Scholar]
- 5.Rasmussen P, Sjo LD, Prause JU, Ralfkiaer E, Heegaard S. Mantle cell Lymphoma in the orbital and adnexal region. Br J Ophthalmol. 2009;93:1047–1051. doi: 10.1136/bjo.2008.146910. [DOI] [PubMed] [Google Scholar]
- 6.Looi A, Gascoyne RD, Chhanabhai M, Connors JM, Rootman J, White VA. Mantle cell Lymphoma in the ocular adnexal region. Ophthalmology. 2005;112:114–119. doi: 10.1016/j.ophtha.2004.07.025. [DOI] [PubMed] [Google Scholar]
